Unveiling Hidden Pathways in Ovarian Cancer: A Novel Perspective on Resistance, Recurrence, and Therapeutic Innovation

MD Nasiruddin Khan, Aubair Manzoor Mani, Om Prakash Agarwal, Jyoti Bajwa , Ramandeep Singh, Md Moidul Isam,

doi:10.5281/zenodo.19681905

Review Paper | Open Access
Volume 04 | Issue 04 | Article Id IJPS/260404079

Unveiling Hidden Pathways in Ovarian Cancer: A Novel Perspective on Resistance, Recurrence, and Therapeutic Innovation
MD Nasiruddin Khan* Aubair Manzoor Mani Om Prakash Agarwal Jyoti Bajwa Ramandeep Singh Md Moidul Isam
School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh,147301, Punjab, India

Abstract

Ovarian carcinoma is one of the most fatal neoplasms of the gynaecological system in the world due to its elusive presentation, diagnostic delay, and high recurrence rate. Although there has been an improvement in the surgical technique, chemotherapeutic regimens, and targeted agents, the improvement in the overall survival has been relatively low. The development of multidrug resistance and relapse of the tumours remains a formidable challenge to clinical practice. The molecular mechanisms that underlie it are in a multifactorial manner and involve the increased capacity to repair DNA damage, the activation of pro-survival signaling pathways, the efflux of chemotherapeutic agents through transporter proteins, and protective interactions within the tumour microenvironment. Moreover, the survival of cancer stem cells (CSCs) and the epithelial-mesenchymal transition (EMT) contribute to tumour repopulation and metastatic spread after treatment. The recent discoveries in these unknown pathways have redefined our understanding of the biology of ovarian cancer to highlight their possible molecular targeting as a source of new therapeutic interventions. Biomarkers related to resistance, recurrence, and prognosis have been revealed by the combination of omics technologies, such as genomics, transcriptomics, and proteomics. New treatment approaches, including overcoming drug resistance and prolonging patient survival, have shown promise, including PARP inhibition, immune checkpoint blockade, and CSC-targeted therapies.

Keywords

Ovarian cancer; Chemoresistance; Tumor microenvironment; Cancer stem cells; Epithelial–mesenchymal transition; PARP inhibitors.

Introduction

Ovarian cancer is one of the most daunting oncology problems in women with the greatest mortality rate among gynaecologic cancer types. Even though it represents a smaller percentage of total cancer occurrence, the lack of certain symptoms at initial stages contributes to its imbalanced fatality rate, thus causing the early diagnosis and limiting treatment solutions [1]. The Global Cancer Observatory (GLOBOCAN) estimates that annual rates exceed 300,000 new cases and 200,000 deaths, most of the patients coming into the country with the advanced disease. Since in many cases early symptoms resemble those of benign conditions, early diagnosis is often made after the disease has spread to the peritoneum or other remote organs, where treatment intervention is no longer effective [2].

The conventional treatment involves maximal cytoreductive surgery and chemotherapy using platinum and taxanes. Although the response rates are high in this method, the relapse happens in about 70 percent of patients within two years [3]. Frequent recurrent tumours have resistance to agents that were effective previously, and thus overall survival is poor. The five-year survival of advanced-stage ovarian cancer is less than 45 0, which has stayed steady over decades. These statistics highlight the urgency of finding new biomarkers and targets of therapeutic interventions in order to enhance patient outcome [4].

Ovarian cancer refers to a heterogeneous group of tumours that have different histopathological and molecular subtypes. The most common type is high grade serous ovarian carcinoma (HGSOC) which represents about 70%percent of cases [5]. The subtype is characterized by TP53 mutations, genomic instability, and defects of homologous recombination repair (HRR) pathways involving BRCA1 and BRCA2 genes. This molecular heterogeneity has an impact on the effectiveness of treatment and prognosis, which explains the necessity of the precision-based approach to treatment [6].

The chemoresistance phenomenon is multi-factorial. Rapid cellular metabolic reprogramming or enhanced DNA repair capabilities, perturbed apoptotic pathways, increased drug efflux through ATP -binding cassettes (ABC) transporters, or altered apoptotic pathways may be adaptations of tumour cells to overcome cytotoxic stress [7]. In addition, the tumour microenvironment (TME) has a protective effect, which supports resistance by means of interactions with the stroma, immune suppression, and hypoxia-related signaling. Hypoxia-inducible factors (HIFs) also stimulate angiogenesis and metabolic adjustment, which also facilitates the survival of tumours during the period of therapeutic stress [8].

The recurrence and resistance of diseases have also been identified as key features of cancer stem cells (CSCs) as emerging evidence. These are self-renewing and pluripotent cells, which are resistant to standard treatments, that eliminate differentiated malignant cells [9]. On the same note, epithelial-mesenchymal transition (EMT) gives cells motility and invasiveness, which promote metastasis and chemoresistance. The combination of the above mechanisms creates a strong tumour ecosystem that is able to resist the normal course of treatments [10].

1.1 Molecular and Cellular Basis of Chemoresistance.

Chemoresistance is still one of the most significant obstacles to achieving long-term remission of ovarian carcinoma. Although the initial administration of platinum-based and taxane-based regimens often causes massive tumour regression, after a while, most patients relapse with neoplasms exhibiting resistance to these drugs [11].

The phenomenon is a complex process, which involves genetic, epigenetic, cellular, and microenvironmental changes, thus enabling malignant cells to escape cytotoxic attack [12].

There is therefore a pressing need to explain the molecular and cellular basis of chemoresistance, to be able to develop newer therapeutic interventions that can reverse or prevent the occurrence of this refractive condition [13].

1.1.1 DNA Damage Repair and Platinum Resistance.

The platinum-based agents, especially cisplatin and carboplatin, are the pillars of the initial treatment regimens in the treatment of epithelial ovarian cancer [14]. The mechanism of cytotoxicity of this chemotherapeutics is the formation of inter- and intra-strand DNA crosslinks that brings about replication fork stalling and eventually induces apoptosis. However, the neoplastic cells can gain the expertise of repairing the platinum induced DNA damage, thus reducing the therapeutic effects and developing resistance to the drug [15].

One of the major determinants of the platinum resistance is the homologous recombination repair (HRR) route. Initial tumours with germline or somatic mutations in BRCA1 or BRCA2 are characterized by increased sensitivity to platinum compounds and poly (ADP -ribose) polymerase inhibitors due to impaired HRR [16]. Nevertheless, acquired resistance can be recovered via secondary mutational events that rescue BRCA activity, which eventually recovers DNA repair capacity. Furthermore, additional support of tumour cell survival under the genotoxic insult can be provided by upregulation of ancillary DNA repair pathways, including nucleotide excision repair (NER) and mismatch repair (MMR) [17].

The modulation of chemosensitivity is also involved in epigenetic silencing of DNA repair loci in promoters with the help of hypermethylation. As an example, the defective mismatch repair and the inappropriate response to treatment is associated with hypermethylation of the MLH1 promoter. All these findings point to the dynamical adaptive capability of tumour cells that can alternatively switch between repair-deficient and repair-proficient cell types under therapeutic stress [18].

1.1.2 Drug Efflux and Transporter-Mediated Resistance.

One of the main processes that leads to chemoresistance is the enhanced expression of ATP-binding cassette (ABC) transporters that can be used to actively release chemotherapeutic agents, thus reducing intracellular drug levels. P-glycoprotein (ABCB1), multidrug resistance protein 1(MRP1/ABCC1), and breast cancer resistance protein (BCRP/ABCG2) are the most comprehensively examined ones in ovarian cancer [19]. High expression of these efflux pumps renders platinum resistance, resistance to paclitaxel, doxorubicin, and topotecan. More importantly, pro-survival signalling cascades such as NF-, PI3K/Akt-, and MAPK/ERK-transcriptional activation are more often than not the drivers of the upregulation of these transporters and provide a simultaneous boost in cellular proliferation and inhibitors of apoptotic processes [20].

Therapeutic approaches aimed at inhibiting efflux transporters either by means of pharmacological antagonists or genetic silencing methods are effective in preclinical models, but the process of translating them into clinical practice has been undermined by the toxicity and target specificity issues [21].

1.1.3 Apoptosis Evasion and Survival Pathways.

One of the characteristics of chemoresistance is apoptotic dysregulation. Apoptotic regulators that play key roles in cancer cell survival are often mutated or altered by epigenomic agents in cancer cells, so that they can avoid undergoing programmed cell death. This reduction of pro-apoptotic proteins, Bax, Bak, and caspase-3, and overexpression of anti-apoptotic family, Bcl-2 and Bcl-xL, favors the cellular balance, shifting it towards survival [22].

Moreover, the PI3K/Akt/mTOR activation contributes to the central mechanism of cell survival and, at the same time, suppresses the occurrence of apoptosis. Constitutive Akt calcium signalling increases glucose metabolism, protein synthesis, and inhibits cytochrome c release by mitochondria. Similarly, NF-KB transcription factor aberrant activation triggers the expression of anti-apoptotic and inflammatory cytokine genes that protect tumour cells against death by drugs [23].

Inhibition of these pathways therapeutically by the use of certain kinase inhibitors or by knockdown by siRNA has shown itself capable of restoring chemosensitivity. Nevertheless, cross-talk of signalling networks can easily result in compensatory stimulation, and this indicates the complexity of activating the survival pathways in ovarian cancer [24].

1.1.4 The Role of the Tumour Microenvironment (TME).

The tumour microenvironment (TME) has a far-reaching effect on chemoresistance through a protective niche of malignant cells. It consists of cancer-associated fibroblasts (CAFs), immune effector cells, endothelial cells and elements of the extracellular matrix (ECM) which dynamically interact with tumour cells [25].

CAFs secrete growth factors (hepatocyte growth factor (HGF), transforming growth factor -b (TGF-b), and fibroblast growth factors (FGFs)) that activate downstream signalling pathways that mediate cell survival, invasion and chemotherapeutic resistance. In addition, the ECM acts as a physical barrier to block drug penetration and induce cell adhesion-mediated drug resistance (CAM-DR) [26].

There is further hypoxia in the TME, which leads to treatment failure. Low oxygen triggers stabilisation of hypoxia-inducible factors (HIF-1 2) leading to the expression of angiogenesis, glycolysis and autophagy-controlling genes, thus facilitating tumour response to stress. Hypoxia also promotes epithelial-to-mesenchymal transition (EMT) and stemness-related programs, which develop a direct relationship between microenvironmental cues and tumour recurrence and metastasis [27].

The need to eliminate the TME is emphasized by modern research in combination with traditional cytotoxic treatment. Anti-angiogenic drugs like bevacizumab impair tumour vessels and amplify chemotherapy but resistance to anti-angiogenic drugs can still occur due to alternative angiogenic pathways[28].

1.1.5 Cancer Stem Cells (CSCs) and Hierarchical Resistance.

A second important model of explaining the persistence of drug-resistant disease is the cancer stem cell (CSC) model. CSCs constitute a small subpopulation of tumour cells that are endowed with self-renewal and differentiation potential and hence maintains growth in tumours despite cytotoxic chemotherapy that has eliminated most cancer cells by differentiation [29].

The common use of markers, including CD44, CD133, ALDH1, and SOX2 is used to detect ovarian CSCs. These cells exhibit innate resistance which can be attributed to their quiescent cell phenotype, effective DNA repair apparatus, and a pronounced increment in the expression of efflux transporters. Moreover, CSCs are resistant to stress during chemotherapy and they can later restart the development of tumours thus leading to reoccurrence of the disease [30].

There is emerging evidence to suggest that CSCs are species residing in niches which are regulated by the tumour microenvironment (TME) and hypoxia. CSC maintenance and self-renewal require the presence of Signalling cascades such as Wnt/ 2 -catenin, Notch, and Hedgehog. Even though preclinical development of therapeutic targeting of these pathways has shown efficacy in depleting CSC populations, these approaches have not been translated to clinical practice due to toxicity issues and redundancy of signalling pathways [31].

2. Recurrence in Ovarian Cancer: Drivers and Dynamics.

The greatest challenge in clinical oncology is ovarian cancer recurrence. Although it is initially responsive to the platinum-based chemotherapy, some 70? percent of patients relapse after two years. The frequent tumours are normally reaping, genetically heterogeneous and not responsive to the conventional forms of therapy. To enhance the survival, long-term survival requires the knowledge of the biological basis of recurrence [32].

3.1 Clonal Evolution and Heterogeneity of Tumours.

Recurrence is also frequent due to the choice and growth of resistant subclones which overcomes early therapy. Primary ovarian tumours have a high level of intratumoral heterogeneity in that they contain several subpopulations in the same lesion. Chemotherapy has a selective pressure effect, eliminating sensitive cells and permitting resistant clones, which are frequently typified by increased DNA repair, anti-apoptotic signalling and stem-like properties, to prevail [33].

Recent single-cell sequencing analyses have shown that recurrent tumours contain distinct mutational states on comparison with their primary counterparts, especially in cell cycle, chromatin remodelling, and immune evasion regulating genes. In this model of clonal evolution, adaptive resistance mechanisms have been stressed as opposed to drug failure [34].

3.2 CSCs and Dormancy of Cancers.

The role of the cancer stem cells (CSCs) in tumour recurrence is critical. Their inherent ability towards self-recovery and dormancy enables them to endure the chemotherapeutic courses. The dormant CSCs can then reawaken and seed secondary lesions which are molecularly different and unresponsive to already used therapies. This microenvironmental-mediated dormancy recursion is an often-used process in which hypoxia and inflammatory cytokines trigger stemness-related signalling pathways, in particular, Want, Notch, and Hedgehog, which keep CSC alive and enable metastatic invasion [35].

3.3 Epithelial Mesenchymal Transition and Metastatic Dissemination.

Epithelial-mesenchymal transition (EMT) is closely related to peritoneal dissemination of ovarian carcinoma. EMT allows the malignant cells to gain the migratory and invasive qualities allowing them to be detached by the original tumour, survive in ascitic fluid, and adhere to the peritoneal surfaces [36]. The isolated cells are often organized into spheroids, three-dimensional masses which exhibit increased anoikic and chemotherapy resistance. During a first-treatment, the remaining spheroids can act as the seeds to the secondary growth of tumours. They have mesenchymal-epithelial transition (MET) ability that allows them to reattach and proliferate at metastatic locations which continues the loop of recurrence [37].

3.4. Micro environmental and Immune modulation.

The tumour microenvironment (TME) changes parallel to the tumour, which promotes recurrence by supporting angiogenesis, immunosuppression and metabolism. The antitumour immunity is suppressed by immunosuppressive representatives of the immune system, including tumour-associated macrophages (TAMs), regulatory T cells (Tregs), and so on, which forms a permissive environment of relapse [38]. Also, vascular endothelial growth factor (VEGF) release under hypoxia improves neovascularization, which is necessary to supply sufficient nutrition to remnant tumour foci. Tumour-stem fibroblasts (CAFs) release extra-cellular matrix proteins, which enhance adhesion of cells and re-colonization [39].

3.5 Clinical Implications.

Recent patterns of recurrence warrant the need to keep an eye on the molecular surveillance and adjustive therapeutic programmes. The use of profiling of circulating tumour DNA (ctDNA) and serial biopsies are becoming useful to identify molecular evolution and predict relapse before clinical presentation. Enhancing mitigation of recurrence and remission can be achieved by targeting dormancy, CSCs and microenvironmental interactions [40].

4. Innovations and Next-generation Strategies in Therapy.

Despite the recent improvements in the treatment of ovarian cancer through surgery and chemotherapy, the survival rate of recurrent ovarian cancer is pathetic. However, an increased knowledge on the molecular resistance mechanisms has enhanced the emergence of novel therapeutic interventions to achieve individualized, sustained disease management [41].

The inhibition of PARP and DNA repair.

The scientific discovery of poly- (ADP-ribose) polymerase (PARP) inhibitor regulation such as olaparib, niraparib, or rucaparib is a breakthrough in the treatment regimen of ovarian carcinoma. The PARP enzymes are crucial in the repair of single-strand lesions of DNA via the base excision repair pathway [42]. PARP pharmacological inhibition leads to the accumulation of DNA damage that leads to synthetic lethality in tumours with BRCA mutations. However, the development of resistance to PARP inhibition has been linked to the occurrence of secondary BRCA reversion mutations and an increased replication-fork protection system. Combinations of PARP get underway are currently being tested, combining PARP-inhibitors with anti-angiogenic agents, immune-checkpoint modulators or ATR-inhibitors in an effort to beat these resistance mechanisms. Immune Checkpoint Blockade and Immunotherapy [43].

Table 1: Targeted therapy classes—PARP inhibitors, anti-angiogenic agents, and PI3K/AKT/mTOR blockers

Sr. No.	Class of Targeted Therapy	Mechanism of Action	Representative Drugs	Therapeutic Indications	Key Clinical Outcomes / Notes	Reference
1.	PARP Inhibitors (Poly ADP-ribose polymerase inhibitors)	Inhibit PARP enzymes involved in DNA single-strand break repair; induce synthetic lethality in BRCA1/2-mutated or homologous recombination–deficient tumours.	Olaparib, Rucaparib, Niraparib, Talazoparib	Ovarian, breast, prostate, and pancreatic cancers with BRCA mutations	Improved progression-free survival (PFS); particularly effective in maintenance therapy post-chemotherapy; emerging resistance remains a challenge.	[44]
2.	Anti-angiogenic Agents	Block VEGF/ VEGFR signaling pathway to inhibit tumour angiogenesis and reduce vascular supply to tumours.	Bevacizumab (anti-VEGF antibody), Sunitinib, Sorafenib, Pazopanib	Colorectal, renal cell, lung, ovarian, and hepatocellular carcinomas	Delay in tumour progression; often used in combination regimens; hypertension and thromboembolic events are common adverse effects.	[45]
3.	PI3K/ AKT/ mTOR Blockers	Inhibit components of the PI3K/ AKT/ mTOR pathway, which regulates cell growth, proliferation, and survival.	Everolimus, Temsirolimus (mTOR inhibitors); Alpelisib (PI3K inhibitor); Capivasertib (AKT inhibitor)	Breast, renal, pancreatic neuroendocrine, and endometrial cancers	Demonstrated benefit in PI3K-mutated or pathway-activated tumours; combination approaches under investigation to overcome adaptive resistance.	[46]

4.2 Immune Checkpoint Blockade and Immunotherapy.

The introduction of immunotherapy has permanently transformed the field of cancer treatment; nevertheless, its effect on the overall ovarian cancer treatment has been insignificant. The responsiveness to anti-PD-1 and anti-CTLA-4 monoclonal antibodies as immune-checkpoint inhibitors (ICIs) is limited by tumour-meditated immune evasion, which is mediated by the expression of PD-L1, T-cell exhaustion, and immunosuppressive tumour micro-environment (TME). In order to increase efficiency, combinatorial regimens including ICIs, conventional chemotherapy, PARP inhibitors or vascular endothelial growth factor (VEGF) antagonists are currently being tested [47]. The areas of intervention are to increase tumour immunogenicity, promote antigen presentation, and reverse immunosuppression. Adoptive cellular therapies such as tumour-infiltrating lymphocytes (TILs) and chimeric antigen receptor (CAR) T cells based on MUC16 can also be regarded as promising modalities although there are challenges associated with heterogeneity of tumour antigens and with potential toxicity [48].

4.3. Anti-Angiogenic and Microenvironment-Targeted Therapy.

The angiogenesis in ovarian carcinoma is the basis of both primary tumour growth and metastatic spread. A monoclonal antibody bevacizumab, a vascular endothelial growth factor (VEGF) antagonist, has shown clinical efficacy in slowing the progression of the disease when it is used together with conventional cytotoxic chemotherapy [49]. However, adaptive resistance can often occur through engagement of countermeasures of angiogenic signalling pathways, such as fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF). The modern therapeutic design is aimed at interfering with these other pathways or normalising aberrant vasculature to maximise drug delivery and promote immune penetration. Inhibition of transforming growth factor-β (TGF-B) and lysyl oxidase (LOX) has become popular as targets to inhibit stromal elements of the TME such as cancer-associated fibroblasts (CAFs) and elements of the extracellular matrix (ECM), which has been shown to reduce desmoplastic barriers in preclinical studies [50].

The fourth one focuses on attacking Cancer Stem Cells and EMT.

The CSCs are considered to be the best therapeutic targets due to their central role in tumour recurrence and chemoresistance. There are also agents that block stemness-related signalling cascades such as Wnt, Notch and Hedgehog pathway inhibitors which are under investigation in combination with cytotoxic chemotherapy [51]. Also, reinstatement of epithelial-mesenchymal transition (EMT) by the action of microRNAs or TGF -b pathway blockage is suggested to re-sensitize tumours to chemotherapeutic agents and block metastatic progression. Drug delivery platforms based on nanoparticles are increasing the accuracy of these inhibitors and they are reducing systemic toxicity at the same time[52].

4.5 Epigenetic Therapies

Epigenetic reprogramming is a prospect of resensitising resistant tumours. Histone deacetylase inhibitors (HDACis) like vorinostat, in combination with DNA methyltransferase inhibitors (DNMTis), e.g. azacitidine can inactivate silenced tumour-suppressor genes and reestablish chemosensitivity [53]. There has been a synergistic effect in epigenetic agents used with immunotherapeutic modalities, with Epigenetic modulation able to increase the expression of tumour antigens and enhance the level of immune recognition. Combination of DNMTi–PARP inhibitors and HDACi–ICI Phase II and III clinical trials are in progress [54].

4.6 Nanomedicine and Smart Drug Delivery Systems

Nanomedicine offers a transformative approach to overcoming pharmacokinetic limitations and multidrug resistance in ovarian cancer therapy. Engineered nanoparticles, liposomes, dendrimers, and polymeric micelles enable controlled and targeted release of chemotherapeutic or biological agents directly to tumour cells while sparing normal tissues. Functionalization with tumour-specific ligands, antibodies, or aptamers enhances selective uptake through receptor-mediated endocytosis [55].

Smart drug delivery platforms—such as stimuli-responsive nanoparticles activated by pH, redox potential, enzymes, or temperature—provide spatiotemporal control over drug release, addressing intratumoural heterogeneity and improving therapeutic efficacy. Furthermore, co-delivery systems integrating small-molecule drugs with nucleic acids (siRNA, miRNA, or CRISPR components) are emerging as powerful tools to modulate gene expression responsible for chemoresistance and recurrence [56].

4.7 Combination Therapies and Synthetic Lethality Approaches

Resistance in ovarian cancer often arises from the redundancy of survival pathways and compensatory repair mechanisms. Combination therapies aim to simultaneously target multiple molecular nodes, thereby preventing escape routes utilized by cancer cells. Integrating PARP inhibitors with anti-angiogenic agents, PI3K/AKT/mTOR inhibitors, or immune checkpoint modulators has shown synergistic effects in clinical settings [57].

Synthetic lethality approaches represent a strategic advancement in this direction. By exploiting defects in DNA damage response pathways—such as BRCA1/2 mutations or homologous recombination deficiencies—these strategies selectively kill tumour cells while sparing normal counterparts. The combination of targeted therapies with nanocarriers enhances this precision, ensuring effective drug concentration at the tumour site and reducing systemic toxicity [58].

Table 2: Overview of Combination Therapies and Synthetic Lethality Approaches in Ovarian Cancer

Sr. No	Therapeutic Strategy	Mechanistic Basis	Representative Agents / Combinations	Therapeutic Rationale	Key Outcomes / Observations	References
1	PARP Inhibitors + Anti-Angiogenic Agents	Inhibition of DNA repair (PARP) coupled with suppression of tumour vasculature (VEGF blockade)	Olaparib + Bevacizumab	Dual targeting enhances hypoxia-induced DNA damage and reduces tumour perfusion, amplifying cytotoxic stress in BRCA-mutant or HR-deficient tumours.	Improved progression-free survival; approved for maintenance therapy in advanced ovarian cancer.	[59]
2	PARP Inhibitors + PI3K/ AKT/ mTOR Blockers	Simultaneous targeting of DNA repair and survival signaling pathways	Niraparib + Alpelisib, Olaparib + Everolimus	PI3K/AKT inhibition downregulates homologous recombination repair genes, increasing PARP inhibitor sensitivity.	Enhanced synthetic lethality; ongoing clinical trials report promising synergistic efficacy.	[60]
3	PARP Inhibitors + Immune Checkpoint Inhibitors	DNA damage–induced neoantigen release augments immune response; checkpoint blockade restores T-cell activity	Olaparib + Pembrolizumab, Niraparib + Dostarlimab	Promotes immune-mediated tumour clearance while maintaining PARP-induced cytotoxicity.	Demonstrated activity in platinum-resistant and recurrent ovarian cancers.	[61]
4	DNA Damage Response (DDR) Inhibitors + Chemotherapy	Potentiation of DNA damage by inhibiting cellular repair processes	ATR inhibitors + Platinum drugs	Enhances efficacy of DNA-damaging agents by blocking repair of chemotherapy-induced lesions.	Shown to delay resistance development and enhance apoptosis.	[62]
5	Synthetic Lethality via BRCA/HRD Targeting	Exploitation of defective homologous recombination (HR) repair in tumour cells	PARP inhibitors (Olaparib, Rucaparib)	Selective killing of HR-deficient cells through accumulation of unrepaired DNA breaks.	Improved outcomes in BRCA-mutated populations; ongoing research in HRD-positive, BRCA–wild-type tumours.	[63]

5. Biomarkers of Early Detection, Resistance, and Prognosis.

The most important in enhancing the outcomes of ovarian cancer is early detection. Regrettably, existing diagnostic devices have a tendency of detecting illness when it is at a very late stage. Establishment of valid biomarkers is thus essential throughout the spectrum of diagnosis, treatment and prognosis [64].

5.1 Diagnostic Biomarkers.

CA-125 serum biomarker is still popular, but it is not very specific and sensitive. The CA-125 biomarker has been associated with human epididymis protein 4 (HE4) to enhance diagnostic precision when used as an algorithm like ROMA (Risk of Ovarian Malignancy Algorithm). MicroRNA-based, exosomes based, and methylation pattern based microRNAs on plasma are emerging as minimally invasive early detection reagents [65].

5.2 Therapy Response Predictive Biomarkers.

PARP-inhibitors and platinum predictive BRCA1/2 mutation and wider homologous recombination deficiency (HRD) status. In the same manner, the expression of PD-L1 and tumour mutational burden (TMB) could be predictors of immunotherapy efficacy, but their validation is still in progress [66]. Real-time information on response of the treatment and changes in resistance mechanisms can be obtained through circulating tumour DNA (ctDNA) and exosomal RNA markers that can be used to alter therapy [67].

5.3 Prognostic Biomarkers.

High expression of ALDH1 (a cancer-stem-cell marker), HIF1 26 and EMT-related transcription factors are some of the markers linked to poor prognosis. Combination of multi-omics evidence, such as genomic, proteomic and metabolomic signatures, is transforming the concept of prognostic modelling, and making risk-adjusted surveillance approaches possible [68].

6. Translational and Clinical Perspectives.

Clinical translation plays the crucial role of the translation link between the laboratory findings and actual practice, thus improving patient survival and quality of life. In the context of ovarian cancer research, translational oncology is the rational combination of molecular biology, nanotechnology, computational modelling, and methodologically organized clinical trial design in speeding up the development of effective therapeutic agents [69]. The field seeks to fill the gap between experimental evidence of proof-of-concept in one direction and regular clinical practice in the other to ensure novel therapeutic platforms, i.e. nanomedicine, targeted therapies and immunomodulators are under rigorous and prognostically valid assessment routes [70].

6.1 From Bench to Bedside

The laboratory discovery-clinical application translational pathway of therapeutic innovation has been significantly shortened by the introduction of next-generation preclinical models (more accurately) recapitulative of human tumour biology [71].

The PDXs are the patient-derived xenografts.

PDX models involve the implantation of human tumour tissues that have been new ready resected and mixed with immunodeficient murine hosts [72]. Contrary to the traditional cell-line xenografts, PDXs preserve the genetic, phenotypic, and microenvironmental heterogeneity of the initial tumour. They therefore facilitate: to increased accuracy of clinical response prediction. And there is discriminating analysis of resistance processes which is dependable application of biodistribution and efficacy of nanomedicine [73]

PDX systems are now considered the gold-standard preclinical models of interrogating complicated therapists, such as nanoparticle-mediated drug delivery, targeted biologics and combinatorial regimens.

Organoid Models

Organoids are 3D and self-organising cultures that have been established out of patient tumour cells. These constructs preserve patient-specific mutational spectra, mutational spectrum, and cell-cell interactions, which makes them useful in:

high throughput drug screening.
individualised choice of therapy.
exploration of the treatment-related toxicity.
assessment of immunotherapeutic, or gene-editing, strategies [74].

Organoid systems can be quickly and scalarly tested compared to PDX models and are now being included in precision oncology workflows [75].

Adaptive Clinical Trials

The conventional approaches to clinical-trial designs are slow and hard in nature. Conversely, adaptive trial designs, including basket, umbrella and platform trials, permit protocol modification in real-time informed by the available accumulating molecular and clinical data [76].

Basket trials compare a single targeted therapy to many tumour types, which have a common biomarker.
Umbrella trials are multidrug trials that combine several targeted agents in one type of cancer, and stratified by molecular subgroups.
Platform trials help to add or discontinue any of the therapy arms based on interim outcomes [77].

These designs allow the rapid evaluation of specific agents, streamlining of dosing regimens, and rapid recognition of groups of patients that are most likely to be helpful [78]. The obstacles to clinical barriers include hand hygiene because of its use during treatment and management. Clinical Barrier Overcoming. Although molecular oncology and drug design have gotten like substantial progress, the challenges inhibit the success of clinical translation [79].

Inter?patient Heterogeneity

Ovarian carcinoma has been highly heterogeneous, with changes in genomic alterations, metabolic signature, tumour microenvironment and immune infiltration. This variability is the cause of discrepancy in the therapeutic responses and renders standardisation of treatment difficult [80].

Toxicity and Off-label Effects of Drug.

Nanotherapeutics and targeted agents still cause systemic toxicity, immunogenicity or organ-specific injury. Strategies that can be used to counter these undesirable effects include optimising delivery systems, design of smart drug-release systems, and controlling particle size and surface chemistry [81].

Acquisition of Therapeutic Resistance.

The major challenge is resistance. Tumours may acquire:

efflux pump overexpression
epigenetic reprogramming
metabolic adaptations
protection in mediated by microenvironment [82].

Serial biopsies, liquid biopsies and serial circulating tumour DNA (ctDNA) using longitudinal studies are necessary to define resistance pathways in real time. The use of Biomarkers and Artificial Intelligence [83]

The challenges of converting clinical barriers require mass validation of predictive and prognostic biomarkers. Multi-omics data and AI-driven clinical decision-support systems can be built in such a way that:

anticipate therapeutic response.
determine the best combinations of drugs.
direct individualised treatment.
detect resistance early

The artificial intelligence increases the ability to process a complicated set of data and helps clinicians create a therapy plan that suits them specifically [84].

Future perspectives

In the future, the search of long-lasting remission in the treatment of the ovarian carcinoma will be conditional upon the evolution of individualised, adaptive and combination-based approaches to the treatment [85]. Multi-omics profiling is also on the horizon of providing a clearer insight into the biology of tumours on a genomic, epigenomic, proteomic, and metabolic scale, providing the foundation of the personalised choice of therapy [86]. The process of drug discovery Aided by AI helps to identify new targets of therapy and streamline drugs. Immuno-metabolic reprogramming at the same time comes up as a mechanism to reestablish antitumour immunity and overcome the suppressive microenvironment that is in most ovarian cancer. Plausible solutions are also being investigated on how to eliminate tumour dormancy which is one of the many causes of recurrence and nano vaccines are being designed to produce a strong and long lasting immunity response [87]. With liquid biopsies, sustained surveillance of the patient will provide possibilities of early intervention, which can result in long-term remission. To achieve these goals, intensive cooperation through large-scale, data-driven consortia that have the capability to harmonize various skills and assets will be required, and eventually, the innovative research would be converted into actual clinical achievement [88]

CONCLUSION

The complexity of modern oncology is a vivid example of the complexity of ovarian cancer, which is characterized by a high level of heterogeneity, adaptive abilities, and resistance to treatment. Even though surgical procedures, chemotherapeutic regimens and targeted procedures have significantly improved, recurrence continues to be the ultimate cause of death. [88]Further understanding of the processes at the molecular level underlying resistance and recurrence has helped to develop new treatment modalities.

The combination of molecular diagnostics, precision therapeutics, and immunomodulatory techniques in integrated treatment paradigms is the key to prospective success. With an adept approach to the interplay between neoplastic cells and the tumour microenvironment, as well as neoplastic cells and the immune system, the next-generation treatment modalities will eventually transform ovarian cancer into a manageable, rather than fatal, chronic illness.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

Not applicable.

Conflict of interest

No conflicts of interest to declare.

CRediT authorship contribution statement

AS: Writing, review & editing the manuscript.: MNK: Conceptualization, writing review, editing, and visualization. PG, editing the manuscript, Conceptualization, and visualization of the manuscript.

Declaration of Competing Interest

The authors assert that they do not have any known financial interests or personal relationships that could be perceived as influencing the work reported in this paper.

Funding

There is no funding agency in this article.

Data availability

Not applicable.

ACKNOWLEDGEMENTS

Special thanks to Shri. Zora Singh, Chairman, DBU, for providing an excellent research platform. This work wouldn’t have been possible without their collective influence.

REFERENCES

Aray?c?, M.E., A. Köse, and H. Ellidokuz, Trends in National Burden of Incidence and Mortality Rates Attributable to Cervical, Uterine, and Ovarian Cancer from 2008 to 2021 in Türkiye: Findings From the Global Burden of Disease Study. Journal of Basic and Clinical Health Sciences, 2025. 9(3): p. 619-627.
McQuade, C., et al., Review of imaging peritoneal disease and treatment. Canadian Association of Radiologists Journal, 2025. 76(2): p. 287-301.
Letai, A. and H. de The, Conventional chemotherapy: millions of cures, unresolved therapeutic index. Nature Reviews Cancer, 2025. 25(3): p. 209-218.
Ettorre, V.M., et al., Personalized Treatment in Ovarian Cancer: A Review of Disease Monitoring, Biomarker Expression, and Targeted Treatments for Advanced, Recurrent Ovarian Cancers. Cancers, 2025. 17(11): p. 1822.
GATTO, A., Prognostic factors in patients with stage III-IV high-grade serous ovarian cancer (HGSOC) following complete resection/R0: FIGO stage, PCI, Fagotti score, HR status.
Brlek, P., et al., Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted Therapies. Cancers, 2025. 17(21): p. 3500.
Oluremi, A. and N. Ali, 95 Targeting Multiple Cancer Hallmarks with Rapamycin-Loaded Gold Nanoparticles—GE11 Peptide Conjugate: A Proteomic Analysis of Pathway Suppression and Cell Death Induction. American Journal of Clinical Pathology, 2025. 164(Supplement_1): p. aqaf121. 361.
Obeagu, E.I., BREAST CANCER CELLS UNDER OXYGEN STRESS: ADAPTATION AND SURVIVAL MECHANISMS. Universal Journal of Pharmaceutical Research, 2025.
El-Tanani, M., et al., Deciphering the role of cancer stem cells: Drivers of tumour evolution, therapeutic resistance, and precision medicine strategies. Cancers, 2025. 17(3): p. 382.
Swamy, K., et al., Review of Epithelial-Mesenchymal Plasticity (EMP) in Cancer: Targeting EMT-MET Double-Bind by Combinations, Timing, and Sequencing (CTS) Strategy. 2025.
El Naggar, O., et al., Abstract A007: NF1 loss of function enhances chemoresistance in high-grade serous carcinoma. Cancer Research, 2025. 85(18_Supplement): p. A007-A007.
Easwaran, H. and A.T. Weeraratna, Unravelling the genetics and epigenetics of the ageing tumour microenvironment in cancer. Nature Reviews Cancer, 2025: p. 1-20.
Gu, Y., et al., Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer. Molecular Biomedicine, 2025. 6(1): p. 2.
KANNAN, K. and M. ARUMUGAM, A Comprehensive Review, Epithelial Ovarian Cancer: A Journey Through Molecular Mechanisms, Clinical Management, And Future Perspectives. International Journal of Environmental Sciences, 2025. 11(6s): p. 825-841.
Olaizola, I., et al., New platinum derivatives selectively cause double-strand DNA breaks and death in Naive and cisplatin-resistant cholangiocarcinomas. Journal of hepatology, 2025.
Tripathi, D., et al., Advancements in Targeted Therapies and Pharmacogenomics for Personalized Breast Cancer Treatment: The Role of Gene SNPs in Treatment Resistance. Current gene therapy, 2025.
Liu, Q., et al., Tumour irradiation induced immunogenic response: the impact of DNA damage induction and misrepair. Radiation Oncology, 2025. 20(1): p. 133.
DeWitt, J.T., M. Raghunathan, and S. Haricharan, Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology. Trends in Cancer, 2025. 11(1): p. 49-61.
Cravo, D.L.d.M., et al., Comparative Analysis of Chemotherapy Resistance Mechanisms in Humans and Companion Animals. Veterinary Sciences, 2025. 12(8): p. 747.
Du, H., et al., Mitochondrial metabolism and cancer therapeutic innovation. Signal Transduction and Targeted Therapy, 2025. 10(1): p. 245.
Yan, Y., et al., Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications. Molecular Cancer, 2025. 24(1): p. 251.
Palabiyik, A.A., The role of Bcl?2 in controlling the transition between autophagy and apoptosis. Molecular Medicine Reports, 2025. 32(1): p. 172.
Kachranlouei, L., et al., Ameliorative effects of osthole on acrylamide-induced neurotoxicity in PC12 cells: Role of oxidative stress, apoptosis and ERK pathways. Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. 398(4): p. 4361-4372.
Vastrad, B. and C. Vastrad, Identifying differentially expressed genes, miRNAs and TFs in major depressive disorder by bioinformatics analysis of next generation sequencing data. 2025.
Pawar, J.S., et al., Cancer-Associated fibroblasts: immunosuppressive crosstalk with tumour-infiltrating immune cells and implications for therapeutic resistance. Cancers, 2025. 17(15): p. 2484.
Heiserman, J.P. and R.J. Akhurst, Diverse Biological Processes Contribute to Transforming Growth Factor β-Mediated Cancer Drug Resistance. Cells, 2025. 14(19): p. 1518.
Zheng, Q., et al., The role of hypoxic microenvironment in rheumatoid arthritis. Frontiers in Immunology, 2025. 16: p. 1633406.
Wang, W., et al., Targeting tumour angiogenesis with traditional Chinese medicine: mechanisms, challenges, and future directions. Tradit Med Res, 2026. 11(5): p. 35.
Lee, H., et al., Cancer stem cells: landscape, challenges and emerging therapeutic innovations. Signal Transduction and Targeted Therapy, 2025. 10(1): p. 248.
Yang, X., et al., Cancer stem cells-derived exosomal TSPAN8 enhances non-stem cancer cells stemness and promotes malignant progression in PDAC. Oncogene, 2025: p. 1-14.
De Abrew, K.N., et al., Exploration of oxidative stress-mediated genetic toxicology modes of action using a pathway analysis, Connectivity Mapping, and transcriptional benchmark dosing-based framework. Toxicological Sciences, 2025: p. kfaf137.
Asiri, A.M., A. Al Ali, and M.H. Abu-Alghayth, Understanding the role of genetics in tumour and cancer biology. Advancements in Life Sciences, 2025. 12(1): p. 35-48.
Manara, M.C., et al., Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma. Journal of Experimental & Clinical Cancer Research, 2025. 44(1): p. 195.
McPherson, A., et al., Ongoing genome doubling shapes evolvability and immunity in ovarian cancer. Nature, 2025. 644(8078): p. 1078-1087.
Huang, A.V., et al., Protein Marker-Dependent Drug Discovery Targeting Breast Cancer Stem Cells. International Journal of Molecular Sciences, 2025. 26(16): p. 7935.
Carbone, L., et al., Clinical implications of epithelial-to-mesenchymal transition in cancers which potentially spread to peritoneum. Clinical and Translational Oncology, 2025: p. 1-14.
Guarino, M., Epithelial-Mesenchymal Transition as a Pathogenetic Mechanism of Sarcomatoid Carcinoma and Carcinosarcoma. Journal of Clinical Practice and Research, 2025. 47(4): p. 345.
Yang, Y., et al., Tumour-associated macrophages remodel the suppressive tumour immune microenvironment and targeted therapy for immunotherapy. Journal of Experimental & Clinical Cancer Research, 2025. 44(1): p. 145.
Yuhendri, V.M., et al., Vitamin D enhances migration but decreases gene expression of vascular endothelial growth factor and tumour necrosis factor-α in Wharton’s jelly mesenchymal stem cells. Indonesian Journal of Medical Laboratory Science and Technology, 2025. 7(1): p. 49-59.
Abdelrahim, M., et al., Feasibility of Personalized and Tumour-Informed Circulating Tumour DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma. JCO Precision Oncology, 2025. 9: p. e2400934.
Nagao, S., et al., The Concept of “Platinum Sensitivity” in Endometrial Cancer. Cancers, 2025. 17(15): p. 2557.
Wang, Z., Y. Liu, and Q. Yang, Navigating PARP Inhibitor Resistance in Ovarian Cancer: Bridging Mechanistic Insights To Clinical Translation. Current Treatment Options in Oncology, 2025: p. 1-23.
Drew, Y., F.T. Zenke, and N.J. Curtin, DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications. Nature Reviews Drug Discovery, 2025. 24(1): p. 19-39.
Ray, A. and M. Opyrchal, Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors. Current Breast Cancer Reports, 2025. 17(1): p. 22.
Chitoran, E., et al., Blocking Tumoural Angiogenesis VEGF/VEGFR Pathway: Bevacizumab—20 Years of Therapeutic Success and Controversy. Cancers, 2025. 17(7): p. 1126.
Liang, X., et al., A meta-analysis of the risk of adverse cardiovascular events in patients with cancer treated with inhibitors of the PI3K/AKT/mTOR signaling pathway. Cardiovascular Toxicology, 2025. 25(2): p. 269-281.
Morva, A., et al., Unleashing the power of CAR-M therapy in solid tumours: a comprehensive review. Frontiers in Immunology, 2025. 16: p. 1615760.
Zhao, X., et al., Advances and obstacles of T cell-based immunotherapy in gynecological malignancies. Molecular Cancer, 2025. 24(1): p. 207.
Zhang, M., et al., Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies. Frontiers in Bioengineering and Biotechnology, 2025. 13: p. 1589841.
Hsu, C.-Y., et al., Melanoma and its fibroblastic allies: the emerging importance of CAFs in immune suppression, ECM modulation, and therapy resistance. Naunyn-Schmiedeberg's Archives of Pharmacology, 2025: p. 1-18.
Liu, J., et al., Hotspots and trends in gastric cancer stem cell research: a visualization and bibliometric analysis. Frontiers in Oncology, 2025. 15: p. 1523465.
Yadav, S.K., et al., Nanomedicine Strategies to Overcome Multi-Drug Resistance in Cancer: Innovations in Targeted Delivery, Tumour Microenvironment Modulation and Synergistic Therapies. 2025.
Bibi, R., et al., Epidrugs in cancer: mechanisms, applications, and future direction. Clinical and Translational Oncology, 2025: p. 1-16.
Suraweera, A., K.J. O’Byrne, and D.J. Richard, Epigenetic drugs in cancer therapy. Cancer and Metastasis Reviews, 2025. 44(1): p. 37.
Alrohaimi, A., et al., Enhancing drug efficacy through nanoparticle-based delivery systems: a study on targeted cancer therapy. International Journal of Surgery, 2025. 111(9): p. 6023-6029.
Mamidi, N., F.F. De Silva, and A.O. Mahmoudsalehi, Advanced disease therapeutics using engineered living drug delivery systems. Nanoscale, 2025. 17(13): p. 7673-7696.
Maqsood, Q., et al., Recent insights into breast cancer: molecular Pathways, epigenetic Regulation, and emerging targeted therapies. Breast Cancer: Basic and Clinical Research, 2025. 19: p. 11782234251355663.
Mustafa, A. and M. Cozzolino, Synthetic Lethality in Pediatric Brain Tumours: Exploiting DNA Repair Defects with PARP and Epigenetic Inhibitors. 2025.
Zhou, Z. and Q. Zhou, Immunotherapy resistance in triple-negative breast cancer: molecular mechanisms, tumour microenvironment, and therapeutic implications. Frontiers in Oncology, 2025. 15: p. 1630464.
Zeng, B., et al., The influence of homologous recombination repair on temozolomide chemosensitivity in gliomas. Carcinogenesis, 2025. 46(2): p. bgaf017.
Zhang, Y., et al., Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. BioRxiv, 2025: p. 2024.05. 21.595159.
Lee, S.-g., et al., DNA damage response inhibitors in cancer therapy: mechanisms, clinical development, and combination strategies. DNA repair, 2025: p. 103887.
Jeong, S., et al., Targeting DNA repair mechanisms in cancer therapy: the role of small molecule DNA repair inhibitors. NAR cancer, 2025. 7(4): p. zcaf040.
Giles, B.M., et al., Utilizing serum-derived lipidomics with protein biomarkers and machine learning for early detection of ovarian cancer in the symptomatic population. Cancer Research Communications, 2025. 5(9): p. 1516-1529.
Singh, A.K., et al., Comparative Meta-Analysis of Carbohydrate Antigen 125 (CA125), Human Epididymis Protein 4 (HE4), and Diagnostic Indices (Risk of Malignancy Index (RMI) and Risk of Ovarian Malignancy Algorithm (ROMA)) for Pre-operative Detection of Ovarian Carcinoma. Cureus, 2025. 17(4).
Anderson, S.A., et al., Predictive biomarkers for immune checkpoint inhibitor (ICI) and poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) in advanced-stage breast carcinoma. Human Pathology Reports, 2025. 40: p. 300775.
Liu, Q., et al., Research Progress on the Combination of PARP Inhibitors (PARPi) and Immune Checkpoint Inhibitors (ICIs). Advanced Biology, 2025. 9(8): p. 2400720.
Yang, Y. and W. Wang, Recent progress in immune evasion mechanisms of triple-negative breast cancer. Journal of Translational Medicine, 2025. 23(1): p. 1314.
Roy, A.A., et al., The Confluence of Nanotechnology and Heat Shock Protein 70 in Pioneering Glioblastoma Multiforme Therapy: Forging Pathways Towards Precision Targeting and Transformation. Advances in Pharmacological and Pharmaceutical Sciences, 2025. 2025(1): p. 1847197.
El-Sahli, S., The Development of Different Strategies Using Clinically Translatable Models for the Treatment of Triple Negative Breast Cancer. 2025, Université d'Ottawa/University of Ottawa.
Kee, J.X., et al., Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs. Chemical Reviews, 2025.
Fulcher, N., et al., The SRG rat as a novel host for an orthotopic patient-derived xenograft model of breast cancer brain metastasis. Scientific Reports, 2025. 15(1): p. 20932.
Sahu, R.C., et al., Machine Learning for Predictive Modeling in Nanomedicine?Based Cancer Drug Delivery. Med Research, 2025.
Kim, J.S., et al., Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancer. Molecular Cancer, 2025. 24(1): p. 162.
Blanchard, Z., et al., PDX models for functional precision oncology and discovery science. Nature Reviews Cancer, 2025. 25(3): p. 153-166.
Sun, H., Advancements in Clinical Trial Methodologies: A Century in Review. International Journal of Applied Technology in Medical Sciences, 2025. 4(1): p. 10-17.
Khazen, W., et al., Basket trials in rare diseases: a systematic review of current practices, methodological challenges, and future directions. Orphanet Journal of Rare Diseases, 2025. 20(1): p. 578.
Shirzad, M., et al., Artificial Intelligence-Assisted Design of Nanomedicines for Breast Cancer Diagnosis and Therapy: Advances, Challenges, and Future Directions. BioNanoScience, 2025. 15(3): p. 354.
KARISHMA, P., et al., Indian Journal of Novel Drug Delivery. Indian Journal of Novel Drug Delivery, 2025. 17(1): p. 12-23.
Villatoro, F.P., Tumour microenvironment and genomic biomarkers for precision oncology in high-grade serous ovarian cancer.
Fan, Y., et al., Recent Developments in Nanoparticle?Hydrogel Hybrid Materials for Controlled Release. Advanced Science, 2025. 12(35): p. e07209.
Li, J., et al., Drug resistance in cancer: molecular mechanisms and emerging treatment strategies. Molecular Biomedicine, 2025. 6(1): p. 111.
Palieri, R., et al., Liquid biopsy in gastrointestinal oncology: clinical applications and translational integration of ctDNA, CTCs, and sEVs. Oncology Reviews, 2025. 19: p. 1702932.
Nori, L.P., et al., Revolutionizing Healthcare: The Impact of AI on Precision Medicine. International Journal of Pharmaceutical Investigation, 2025. 15(2).
Takamoto, T., et al., Chronological evolution in liver resection for hepatocellular carcinoma: Prognostic trends across three decades in early to advanced stages. European Journal of Surgical Oncology, 2025. 51(2): p. 109461.
Mukherjee, A., et al., From data to cure: A comprehensive exploration of multi-omics data analysis for targeted therapies. Molecular biotechnology, 2025. 67(4): p. 1269-1289.
Keisari, Y., Tumour destruction in situ as a tool to trigger a robust anti-tumour immune response. South East European Journal of Immunology, 2025. 8(CITIM): p. 041-041.
Islam, S. and H.A. Mohna, COMPARATIVE ANALYSIS OF POLITICAL ECONOMY MODELS IN SOUTH ASIA AND THEIR IMPACT ON PUBLIC SECTOR REFORM. Review of Applied Science and Technology, 2025. 3(01): p. 01-39.